Breast Cancer News, Features & Updates

October 8, 2026 — The FDA has approved Tukysa (tucatinib) combined with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer after induction treatment.

September 8, 2026 — The FDA has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation.

An expert explains who may benefit from elacestrant (Orserdu), how this oral SERD works, its side effects, and what to expect.

An expert explains who may benefit from imlunestrant (Inluriyo), how this oral SERD works, its side effects, and what treatment involves.

Two young women chat about the importance of finding community when you’re diagnosed with early breast cancer.

Two early breast cancer survivors share what helped them manage work, medical leave, finances, and returning to the job after treatment.

Through breast cancer, Robin Roberts learned the value of self-advocacy, support, and trusting her instincts.

July 15, 2026 — The FDA has approved Revtorpyk (gedatolisib) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer without a PIK3CA mutation.

June 26, 2026 — The FDA has approved Ibrance (palbociclib) combined with trastuzumab, with or without pertuzumab, plus endocrine therapy as ongoing maintenance treatment for adults with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer whose disease is controlled after induction therapy with a taxane and anti‑HER2 therapy.

June 25, 2026 — The FDA has approved sacituzumab govitecan-hziy (Trodelvy) to treat adults with certain types of triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy and, in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), to treat adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1.

May 26, 2026 — The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate, for first-line treatment of unresectable or metastatic triple-negative breast cancer in adults who are not eligible for PD-1/PD-L1 immunotherapy.

May 18, 2026 — The FDA has cleared new neoadjuvant and adjuvant uses for Enhertu (fam-trastuzumab deruxtecan-nxki) in adults with HER2-positive early breast cancer, positioning the medicine earlier in care.

May 4, 2026 — The FDA approved Veppanu (vepdegestrant) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, with disease progression following at least one line of endocrine therapy and as detected by an FDA-authorized test. It is the first time the FDA has approved a proteolysis targeting chimera (PROTAC), a type of heterobifunctional protein degrader therapy.

If you want to try cannabis for some extra relief from HR+/HER2- breast cancer symptoms and treatment side effects, you should know what it can and can’t do and what the risks may be for someone living with breast cancer.

December 17, 2025 — Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with another medicine, pertuzumab, as the first-line treatment for adults with HER2-positive breast cancer that has spread (metastatic) or cannot be removed with surgery (unresectable).

If you have estrogen receptor-positive breast cancer, you may develop an ESR1 mutation at some point. Find out what they are, and learn about promising new treatments.

If you’ve been diagnosed with stage two or stage three breast cancer, a clinical trial is a great way to ensure you get cutting-edge treatment. Here’s what you need to know.

Treating HR+/HER2-negative metastatic breast cancer typically involves more than one treatment at a time. Find out what these combinations are and how your doctor chooses them.

What do doctors take into consideration when deciding on a course of treatment for HR+/HER2- metastatic breast cancer?

Learn how exercise may help lower the chances of your breast cancer returning.

For many women of color, accessing timely breast cancer care involves overcoming hurdles that complicate their treatment.

Breast cancer at work: How to handle whether or not to tell your boss, co-workers, and human resources department about your breast cancer diagnosis.

Ignoring your instincts could cost you in the long run. Three women share their stories.

September 26, 2025 — The FDA approves Inluriyo (imlunestrant), a new oral treatment for people whose locally advanced or metastatic breast cancer is ER-positive, HER2-negative, and has a faulty ESR1 gene.

Learn how to make informed breast cancer treatment decisions with limited time. Get expert guidance on diagnosis, options, and next steps.

It’s human nature to have anxiety about side effects from breast cancer treatments. New approaches and solid support will help you through.

Tamoxifen’s strong side effects can overwhelm. Explore why some women consider quitting and what you might do instead.

Are you considering a second opinion for your breast cancer treatment? Find out what others did.

Out of any cancer, breast cancer has the highest treatment costs, and figuring out how to pay for treatment can be stressful and overwhelming. Learn how you can take steps to pay for treatment — with or without health insurance.

Here’s what an oncologist gives for tips and treatments to reduce breast cancer recurrence.

What do you tell your friends and family about your breast cancer diagnosis? Learn some tips on what to say and when to say it.

You want the most effective treatment for your breast cancer. Learn how molecular diagnostics can guide your doctors toward a treatment that works best for your tumor.

Your doctor says there's a high risk your cancer will come back. Find out ways to boost your defenses, and how to lean on your past experience if recurrence does happen.

Breast changes after cancer treatment are normal. Here’s what you may see after surgery or radiation, and when to see your doctor about breast changes.

If you want to try cannabis for some extra relief from HR+/HER2- breast cancer symptoms and treatment side effects, you should know what it can and can’t do and what the risks may be for someone living with breast cancer.

If you have hormone positive breast cancer, you’re likely a candidate for endocrine therapy. Here’s what you need to know about this type of treatment.

What can you expect before, during, and after your mastectomy? Get practical advice on your surgery, including what to bring to the hospital, what to have on hand at home, and more.

How do diet, alcohol, obesity, and other factors affect your chances of breast cancer recurrence? Oncologist Jane Meisel, MD, discusses best practices for lowering risk.

Breast cancer treatments are life saving, but they often come with their own challenging side effects. Oncologist Jane Meisel, MD, offers advice for managing the most common issues.

Two oncologists answer the most common early-stage breast cancer questions in this breast cancer Reddit AMA.

July 23, 2025 — For women under 40, breast cancer recurrence risk may be lower than previous estimates suggested. And new research supports patient choice for surgical treatment.

New research is showing that some people who have breast cancer may not need as much treatment as once thought. Learn more from the ASCO Annual Meeting.

The cost of having cancer can ruin your finances. And it’s not just the treatments. An ASCO panel addressed financial toxicity.

Researchers at the ASCO meeting presented on top issues that affect breast cancer survivors. Learn about the importance of follow-up care.

June 11, 2025 — At least 4 out of 10 women have dense breast tissue and may need testing beyond a standard mammogram. Two new studies help clarify your next steps.

April 1, 2025 — U.S. breast cancer deaths are no longer decreasing in women younger than 40, older than 74, or of Asian, Hispanic, or Native American descent. Experts share what they think is behind these and other disparities.

March 4, 2025 — A lumpectomy plus radiation is very effective for treating stage zero cancer, but new research suggests that active monitoring may be just as good.

January 28, 2025 — The FDA has approved fam-trastuzumab deruxtecan, marketed under the brand name Enhertu, as a new treatment for certain types of advanced breast cancer that have spread or cannot be removed with surgery.

January 21, 2025 — The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.